34,425 Shares in Denali Therapeutics Inc. $DNLI Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) during the second quarter, HoldingsChannel.com reports. The firm bought 34,425 shares of the company’s stock, valued at approximately $885,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Denali Therapeutics in the second quarter worth $26,000. Global Retirement Partners LLC acquired a new stake in shares of Denali Therapeutics in the second quarter valued at $28,000. Allworth Financial LP purchased a new position in Denali Therapeutics in the second quarter valued at $47,000. Headlands Technologies LLC purchased a new position in Denali Therapeutics in the second quarter valued at $26,000. Finally, Johnson Financial Group Inc. acquired a new position in Denali Therapeutics during the 3rd quarter worth $29,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Analysts Set New Price Targets

DNLI has been the topic of several recent research reports. Wedbush restated an “outperform” rating and set a $26.00 price target on shares of Denali Therapeutics in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Wall Street Zen upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Friday, July 17th. Finally, Morgan Stanley boosted their target price on shares of Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.85.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $24.00 on Monday. The company has a market capitalization of $3.84 billion, a price-to-earnings ratio of -8.45 and a beta of 1.01. Denali Therapeutics Inc. has a 52-week low of $12.58 and a 52-week high of $27.30. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average price of $24.62 and a 200 day moving average price of $21.72.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $2.15 million. During the same quarter in the prior year, the firm posted ($0.72) earnings per share. Research analysts predict that Denali Therapeutics Inc. will post -2.67 EPS for the current fiscal year.

Insider Activity

In related news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider owned 281,763 shares in the company, valued at $7,063,798.41. This trade represents a 1.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 9.70% of the stock is currently owned by company insiders.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.